Patents by Inventor Katherine Donovan

Katherine Donovan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Ligands to cereblon (CRBN)
    Patent number: 12110292
    Abstract: Disclosed are compounds with immunomodulatory activity, methods of making the compounds, pharmaceutical compositions containing the compounds, and methods of using the compounds to treat diseases or disorders characterized or mediated by dysfunctional protein activity.
    Type: Grant
    Filed: November 11, 2022
    Date of Patent: October 8, 2024
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Nathanael Gray, Tinghu Zhang, Eric Fischer, Zhixiang He, Guangyan Du, Katherine Donovan, Radoslaw Nowak, Jing Ting Christine Yuan
  • INHIBITORS AND DEGRADERS OF PIP4K PROTEIN
    Publication number: 20240277852
    Abstract: The present invention relates to compounds, compositions, and methods for treating diseases or conditions by modulating (e.g., reducing) the level or activity of at least one of PIP4K2A, PIP4K2B, and PIP4K2C.
    Type: Application
    Filed: May 19, 2022
    Publication date: August 22, 2024
    Applicants: DANA-FARBER CANCER INSTITUTE, INC., CORNELL UNIVERSITY
    Inventors: Nathanael S. Gray, Mingxing Teng, Eric Wang, Jie Jiang, Tinghu Zhang, Lewis C. Cantley, Eric S. Fischer, Katherine A. Donovan
  • COMPOUNDS FOR TARGETED PROTEIN DEGRADATION OF KINASES
    Publication number: 20240269139
    Abstract: The present invention relates to bifunctional compounds for targeted kinase degradation, methods for treating diseases or conditions mediated by aberrant kinase activity, and methods for identifying degradable kinases and optimal kinase:scaffold pairs.
    Type: Application
    Filed: October 26, 2021
    Publication date: August 15, 2024
    Applicants: DANA-FARBER CANCER INSTITUTE, INC., Korea Institute of Science and Technology (KIST)
    Inventors: Nathanael S. Gray, Eric S. Fischer, Fleur M. Ferguson, Katherine Donovan, Jonathan W. Bushman, Taebo Sim, Debabrata Bhunia, SeongShick Ryu
  • Bispecific degraders
    Patent number: 12060366
    Abstract: Disclosed are degraders, pharmaceutical compositions containing them, and methods of making and using the degraders to treat diseases and disorders characterized by aberrant protein activity that can be targeted by cereblon.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: August 13, 2024
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Nathanael Gray, Tinghu Zhang, Eric Fischer, Alyssa Verano, Zhixiang He, Guangyan Du, Katherine Donovan, Radoslaw Nowak, Jing Ting Christine Yuan
  • CLASS IIA HISTONE DEACETYLASE (HDAC) DEGRADER LIGANDS AND METHODS OF USE THEREOF
    Publication number: 20240246956
    Abstract: The present invention relates to bifunctional compounds, compositions, and methods for treat diseases or conditions mediated by aberrant activity of at least one class IIa histone deacetylase (HDAC4/5/7/9).
    Type: Application
    Filed: May 2, 2022
    Publication date: July 25, 2024
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Eric S. Fischer, Yuan Xiong, Katherine Donovan
  • SMALL MOLECULE DEGRADERS OF PHOSPHATIDYLINOSITOL-5-PHOSPHATE 4-KINASE TYPE 2 AND USES THEREOF
    Publication number: 20240245786
    Abstract: The present invention relates to bifunctional compounds, compositions, and methods for treating diseases or conditions by modulating (e.g., reducing) the level or activity of at least one of PIP4K2A, PIP4K2B, and PIP4K2C.
    Type: Application
    Filed: December 22, 2021
    Publication date: July 25, 2024
    Applicants: DANA-FARBER CANCER INSTITUTE, INC., CORNELL UNIVERSITY
    Inventors: Nathanael S. Gray, Tinghu Zhang, Lewis C. Cantley, Sindhu Carmen Sivakumaren, Theresa Manz, Eric Wang, Wenzhi Ji, Eric S. Fischer, Katherine Donovan
  • CRBN modulators
    Patent number: 12030892
    Abstract: Disclosed are degraders, pharmaceutical compositions containing them, and methods of making and using the degraders to treat diseases and disorders characterized by dysregulated or dysfunctional protein activity that can be targeted by cereblon.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: July 9, 2024
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael Gray, Tinghu Zhang, Eric Fischer, Alyssa Verano, Zhixiang He, Guangyan Du, Katherine Donovan, Radoslaw Nowak, Jing Ting Christine Yuan
  • METHODS TO PREVENT TERATOGENICITY OF IMID LIKE MOLECULES AND IMID BASED DEGRADERS/PROTACS
    Publication number: 20240142437
    Abstract: Presented are methods of assessing the teratogenicity of agents by measuring the degradation of SALL4, and related compounds with reduced teratogenicity. Provided herein is a method for assessing the teratogenicity of an agent comprising: contacting an agent with SALL4; and measuring levels of SALL4, wherein the agent is teratogenic if SALL4 levels are substantially reduced in the presence of the agent relative to in the absence of the agent.
    Type: Application
    Filed: September 22, 2023
    Publication date: May 2, 2024
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Eric S. Fischer, Katherine Donovan
  • SULFONAMIDE DERIVATIVES FOR PROTEIN DEGRADATION
    Publication number: 20240083847
    Abstract: DCAF15 is a substrate recognition (adaptor) protein of E3 ubiquitin ligase. Disclosed herein are compounds that recruit ubiquitin ligase CRL4DCAF15, to a target RNA recognition motif (RRM), causing its degradation. Also disclosed herein are compositions and methods of use in treating associated disorders and diseases.
    Type: Application
    Filed: September 29, 2023
    Publication date: March 14, 2024
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael S. Gray, Eric Fischer, Hojong Yoon, Tinghu Zhang, Tyler Faust, Katherine Donovan, Quan Cai, Zhengnian Li
  • Sulfonamide derivatives for protein degradation
    Patent number: 11807606
    Abstract: DCAF15 is a substrate recognition (adaptor) protein of E3 ubiquitin ligase. Disclosed herein are compounds that recruit ubiquitin ligase CRL4DCAF15, to a target RNA recognition motif (RRM), causing its degradation. Also disclosed herein are compositions and methods of use in treating associated disorders and diseases.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: November 7, 2023
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael S. Gray, Eric Fischer, Hojong Yoon, Tinghu Zhang, Tyler Faust, Katherine Donovan, Quan Cai, Zhengnian Li
  • LIGANDS TO CEREBLON (CRBN)
    Publication number: 20230312575
    Abstract: Disclosed are compounds with immunomodulatory activity, methods of making the compounds, pharmaceutical compositions containing the compounds, and methods of using the compounds to treat diseases or disorders characterized or mediated by dysfunctional protein activity.
    Type: Application
    Filed: November 11, 2022
    Publication date: October 5, 2023
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael Gray, Tinghu Zhang, Eric Fischer, Zhixiang He, Guangyan Du, Katherine Donovan, Radoslaw Nowak, Jing Ting Christine Yuan
  • Small molecule degraders of polybromo-1 (PBRM1)
    Patent number: 11771697
    Abstract: The present invention relates to compounds, compositions and methods for treating diseases or conditions mediated by proteins of the SWI/SNF chromatin-remodeling complex, including PB1.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: October 3, 2023
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Eric Fischer, Nathanael Gray, Radoslaw Nowak, Katherine Donovan, Tinghu Zhang, Yao Liu
  • SELECTIVE HDAC6 DEGRADERS AND METHODS OF USE THEREOF
    Publication number: 20230011665
    Abstract: The present invention relates to bispecific compounds, compositions, and methods for treating diseases or conditions mediated by aberrant histone deacety lase 6 (HDAC6) activity.
    Type: Application
    Filed: November 5, 2020
    Publication date: January 12, 2023
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Eric S. Fischer, Yuan Xiong, Katherine Donovan, Nicholas Eleuteri
  • SELECTIVE HISTONE DEACETYLASE (HDAC) DEGRADERS AND METHODS OF USE THEREOF
    Publication number: 20220401564
    Abstract: The present invention relates to bifunctional compounds, compositions, and methods for treating diseases or conditions mediated by aberrant histone deacetylase (HCADC) (e.g., HDAC3) activity.
    Type: Application
    Filed: November 5, 2020
    Publication date: December 22, 2022
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Eric S. Fischer, Yuan Xiong, Katherine Donovan, Nicholas Eleuteri
  • Ligands to cereblon (CRBN)
    Patent number: 11530219
    Abstract: Disclosed are compounds with immunomodulatory activity, methods of making the compounds, pharmaceutical compositions containing the compounds, and methods of using the compounds to treat diseases or disorders characterized or mediated by dysfunctional protein activity.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: December 20, 2022
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael Gray, Tinghu Zhang, Eric Fischer, Zhixiang He, Guangyan Du, Katherine Donovan, Radoslaw Nowak, Jing Ting Christine Yuan
  • SELECTIVE DUAL HISTONE DEACETYLASE 6/8 (HDAC6/8) DEGRADERS AND METHODS OF USE THEREOF
    Publication number: 20220387604
    Abstract: The present invention relates to bifunctional compounds, compositions, and methods for treating diseases or conditions mediated by aberrant histone deacetylases 6 and 8 (HDAC6/8) activity.
    Type: Application
    Filed: November 5, 2020
    Publication date: December 8, 2022
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Eric S. Fischer, Yuan Xiong, Katherine Donovan, Nicholas Eleuteri
  • DEGRADATION OF AKT BY CONJUGATION OF ATP-COMPETITIVE AKT INHIBITOR GDC-0068 WITH E3 LIGASE LIGANDS AND METHODS OF USE
    Publication number: 20220226481
    Abstract: Disclosed are bifunctional compounds comprising a GDC-0068 analog that binds AKT isoforms AKT1, 2 and 3, pharmaceutical compositions, and methods for treating diseases or conditions mediated by dysfunctional AKT activity.
    Type: Application
    Filed: April 8, 2020
    Publication date: July 21, 2022
    Applicants: DANA-FARBER CANCER INSTITUTE, INC., BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
    Inventors: Nathanael Gray, Inchul You, Tinghu Zhang, Eric Fischer, Katherine Donovan, Emily Erickson, Alex Toker
  • DEGRADERS OF KELCH-LIKE ECH-ASSOCIATED PROTEIN 1 (KEAP1)
    Publication number: 20220177466
    Abstract: The present invention relates to bifunctional compounds, compositions, and methods for treating diseases or conditions mediated by Kelch-like ECH-associated protein 1 (KEAP1). In some aspects, the present invention is directed to methods of treating diseases or disorders involving dysfunctional (e.g., dysregulated) KEAP1 activity, that entails administration of a therapeutically effective amount of a bifunctional compound of formula I or a pharmaceutically acceptable salt or stereoisomer thereof, to a subject in need thereof.
    Type: Application
    Filed: April 7, 2020
    Publication date: June 9, 2022
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael Gray, Tinghu Zhang, Guangyan Du, Nathaniel Henning, Jie Jiang, Eric Fischer, Katherine Donovan
  • CDK2/5 DEGRADERS AND USES THEREOF
    Publication number: 20220153722
    Abstract: The present invention relates to bifunctional compounds, compositions, and methods for treating diseases or conditions mediated by dysfunctional cyclin-dependent kinase 2 (CDK2) and CDK5 activity.
    Type: Application
    Filed: April 2, 2020
    Publication date: May 19, 2022
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael Gray, Nicholas Kwiatkowski, Eric Fischer, Katherine Donovan, Tinghu Zhang, Mingxing Teng, Jie Jiang
  • DEGRADERS OF WEE1 KINASE
    Publication number: 20220047709
    Abstract: Disclosed are bifunctional compounds (degraders) that target Wee1 tyrosine kinase for degradation. Also disclosed are pharmaceutical compositions containing the degraders and methods of using the compounds to treat disease.
    Type: Application
    Filed: September 26, 2019
    Publication date: February 17, 2022
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael S. Gray, David Scott, Zhengnian Li, Benika J. Pinch, Calla Olson, Eric S. Fischer, Radoslaw P. Nowak, Katherine A. Donovan